Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0034 | 0.2407 | 0.2407 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0056 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0028 | 0 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0056 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0056 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0056 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0056 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0056 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0056 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0056 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0056 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0056 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0056 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0056 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0028 | 0 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0028 | 0.0151 | 0.0151 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0056 | 1 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0056 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0056 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0049 | 0.7743 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0034 | 0.2407 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0056 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0056 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0056 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0056 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0056 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0056 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0049 | 0.7743 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0056 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (ADMET) | = 0 % | Cytotoxicity against human 2209-23 cells at 20 uM | ChEMBL. | 17317178 |
IC50 (functional) | > 350 uM | Cytotoxicity of the compound against L1210 cells. | ChEMBL. | 10425099 |
IC50 (functional) | > 350 uM | Cytotoxicity of the compound against KB cells. | ChEMBL. | 10425099 |
IC50 (functional) | > 350 uM | Cytotoxicity of the compound against L1210 cells. | ChEMBL. | 10425099 |
IC50 (functional) | > 350 uM | Cytotoxicity of the compound against KB cells. | ChEMBL. | 10425099 |
Inhibition (functional) | = 0 % | Antiviral activity against HCV 1b replicon in human 2209-23 cells assessed as inhibition of viral replication at 20 uM | ChEMBL. | 17317178 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.